Larimar Therapeutics
Tom Hamilton is the current President, Chief Executive Officer and owner of Construction Forms, Inc. (Con Forms), an industrial manufacturing company based in Port Washington, WI. In addition, he serves as a managing member of FA Life Sciences, an early stage biotech investment company focused on bridging the gap to cure Friedreich’s ataxia. Mr. Hamilton is also a Director and Executive Committee member of the Friedreich’s Ataxia Research Alliance (FARA). Prior to Con Forms, he was a managing director and strategic advisor to the head of fixed Income, currencies and commodities at Barclays Capital in New York. Mr. Hamilton was responsible for the build out of the Global Securitized Products businesses at Barclays along with Municipal Trading and Investment Banking. Prior to Barclays Tom worked at Citigroup Global Markets and began his career at Salomon Brothers, Inc. in New York.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.